Meeting Agenda & Location
Download: Agenda (pdf) Wednesday October 10th 7:30 am - Registration Opens 8:30 am - Welcome, Announcements and Keynote Speaker Introduction Karl Salzwedel, NIAID 8:40 am - Keynote I: Anthony Fauci, NIAID Martin Delaney Collaboratory Research Highlights 9:00 am - I4C: Combined Immunological Approaches to Cure HIV-1 Dan Barouch, Beth Israel Deaconess Medical Center 9:20 am - BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy Luis Montaner, Wistar Institute 9:40 am - BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication Douglas Nixon, Weill Cornell Medicine 10:00 am - CARE: Collaboratory of AIDS Researchers for Eradication David Margolis, University of North Carolina, Chapel Hill 10:20 am - defeatHIV: Delaney Cell and Genome Engineering Initiative Keith Jerome, Fred Hutchinson Cancer Research Center 10:40 am - DARE: Delaney AIDS Research Enterprise to Cure HIV Steven Deeks, University of California, San Francisco 11:00 am - Break (Poster Viewing and Networking) Session I: Finding the Reservoir * Chairs: Janice Clements, Johns Hopkins University and Elizabeth Connick, University of Arizona 11:25 am - HIV-1 Modulates Host Gene Expression at the Integration Site Ya-Chi Ho, Yale School of Medicine 11:40 am - Characterizing Host Pathways that Regulate Latency in a Primary Cell Model Edward Browne, University of North Carolina, Chapel Hill 11:55 am - Characterization of Latent and Active HIV Reservoirs in Blood and Tissues Nicolas Chomont, Université de Montréal 12:10 pm - Novel In Situ Approaches to Characterize Viral Reservoirs Jacob Estes, Oregon Health & Science University 12:25 pm - Developing Imaging Approaches to Define the Early Mucosal SIV Reservoir Thomas Hope, Northwestern University 12:40 pm - Panel Discussion 1:00 pm - Lunch (On Your Own) 2:00 pm - Poster Session Session II: Quantifying the Reservoir * Chairs: Nancie Archin, University of North Carolina, Chapel Hill and John Mellors, University of Pittsburgh 3:15 pm - Genomic Landscapes of HIV, SIV, and SHIV: Relevance to Measuring the Latent Reservoir in Cure Studies Robert Siliciano, Johns Hopkins University 3:30 pm - Insights into HIV Reservoir Assay Performance from the RAVEN Program Michael Busch, Blood Systems Research Institute 3:45 pm - Determining Early HIV Decay Dynamics upon Treatment Initiation Elizabeth Anderson, HIV Dynamics and Replication Program, NCI 4:00 pm - A Phylogenetic Approach to Estimate Integration Dates of Individual Latent HIV Sequences Within-Host Zabrina Brumme, Simon Fraser University 4:15 pm - Using Reactivation Rates to Quantify the Viral Reservoir Brandon Keele, AIDS and Cancer Virus Program, NCI 4:30 pm - Panel Discussion 5:00 pm - Adjourn Day 1 Thursday October 11th 8:25 AM - Announcements and Keynote Speaker Introduction Lillian Kuo, NIAID 8:30 AM - Keynote II: CD4-mimetic Compounds: Sensitization of HIV-1 to Sub-dominant Antibody Responses Joseph Sodroski, Dana-Farber Cancer Institute Session III: Overcoming Latency * Chairs: Richard D’Aquila, Northwestern University and Vicente Planelles, University of Utah 9:00 am - Dual TLR2 and TLR7 Agonists as HIV Latency-reversing Agents Amanda Macedo, George Washington University 9:15 am - BCL-2 Antagonism Enables CTL-Mediated Elimination of Ex Vivo CD4 Reservoirs R. Brad Jones, Weill Cornell Medicine 9:30 am - Systemic In Vivo Induction of the Latent HIV Reservoir via the Non-canonical NF-kB Signaling Pathway J. Victor Garcia, University of North Carolina, Chapel Hill 9:45 am - Latency Reversal in Nonhuman Primates Ann Chahroudi, Emory University 10:00 am - Combination Therapies with TLR7 Agonists Devi SenGupta, Gilead Sciences 10:15 am - Panel Discussion 10:45 am - Break (Poster Viewing and Networking) Session IV: Killing Reservoir Cells * Chairs: Sharon Riddler, University of Pittsburgh and Lydie Trautmann, Military HIV Research Program 11:05 am - Towards HIV-1 Remission with AAV-expressed eCD4-Ig Matthew Gardner, Scripps Research Institute 11:20 am - How Many mAbs to Target the Latent Reservoir? Guido Ferrari, Duke University 11:35 am - Novel Humanized Mouse Model to Investigate In Vivo Activation and bNAb-mediated Depletion of Patient-Derived HIV Latent Reservoirs Harris Goldstein, Albert Einstein College of Medicine 11:50 am - Trafficking of Stem Cell-Derived CAR T-Cells to B-Cell Follicles in SHIV-Infected Nonhuman Primates Christopher Peterson, Fred Hutchinson Cancer Research Center 12:05 pm - Why HIV-specific T cells Engineered with CARs Work Better than Those Engineered with TCRs James Riley, University of Pennsylvania 12:20 pm - HIV-Resistant CAR T Cells in SHIV-infected Non-human Primates Thor Wagner, Seattle Children's Hospital 12:35 pm - Panel Discussion 1:00 pm - Lunch (On Your Own) 2:00 pm - Poster Session Session V: Immunomodulation and Immunologic Control of Viremia * Chairs: Jonathan Karn, Case Western Reserve University and Jeffrey Lifson, Frederick National Laboratory 3:00 pm - Understanding CD8+ T Cell Function During Antiretroviral Therapy Afam Okoye, Oregon Health & Science University 3:15 pm - Generating Functional HIV-specific CD8+ T Cells Rachel Rutishauser, University of California, San Francisco 3:30 pm - Myeloid-derived Suppressor Cells Expand During Analytic treatment Interruption and Decrease Anti-viral T cell Responses in Combinatorial HIV Curative Therapy Sandra Dross, University of Washington 3:45 pm - Combination Immunotherapy to Induce Viral Remission James Whitney, Beth Israel Deaconess Medical Center 4:00 pm - Neutralizing Antibody-Based HIV Cure Strategies Dan Barouch, Beth Israel Deaconess Medical Center 4:15 pm - Effects of Broadly Neutralizing Antibody Combinations in HIV-1 Infection Marina Caskey, Rockefeller University 4:30 pm - Panel Discussion 5:00 pm - Adjourn Day 2 Friday October 12th 8:25 AM - Announcements and Keynote Speaker Introduction Roger Miller, NIAID 8:30 AM - Keynote III: Silencing the HIV-1 Reservoir Susana Valente, Scripps Research Institute Session VI: Clinical Trials and Community Engagement * Chairs: Adriana Andrade, NIAID and Joseph Eron, University of North Carolina, Chapel Hill Panelists: Richard Jeffreys, Treatment Action Group and A. Toni Young, Community Education Group 9:00 am - Meeting Report: Framework for Initiating Pediatric Studies of HIV Cure Interventions Deborah Persaud, Johns Hopkins University 9:15 am - Analytical Treatment Interruption in HIV Cure Trials – Report of a Consensus Workshop Boris Juelg, Ragon Institute 9:30 am - Acceptability of Target Product Profiles for an HIV Cure Regimen According to Adults Living with HIV in the U.S. Karine Dubé, University of North Carolina, Chapel Hill 9:45 am - The Last Gift: Performing HIV Cure Research at the End of Life Sara Gianella Weibel, University of California, San Diego 10:00 am - Panel Discussion 10:30 am - Break (Poster Viewing and Networking) Session VII: Viral Rebound and Post Treatment Control * Chairs: Rajesh Gandhi, Massachusetts General Hospital and Nelson Michael, Military HIV Research Program 10:50 am - Lessons Learned from Brief ATI Trials in the RV254 Cohort to Inform Future ATI Designs Jintanat Ananworanich, Military HIV Research Program 11:05 am - Preliminary Testing of a bNAb Susceptibility Screening Assay Katherine Bar, University of Pennsylvania 11:20 am - The Majority of the Replication-competent Virus in the Latent Reservoir Originates from Viruses Replicating Near the Time of ART Initiation Sarah Joseph, University of North Carolina, Chapel Hill 11:35 am - Impact of Analytical Treatment Interruption on HIV Dynamics Tae-Wook Chun, NIAID 11:50 am - Understanding Post-Treatment HIV Control Jonathan Li, Brigham and Women's Hospital 12:05 pm - Panel Discussion 12:30 pm - Closing Remarks, Adjourn *Sessions will be comprised of short 12-minute talks in a total 15-minute slot per speaker, then followed by a 20 to 30-minute panel discussion with all speakers Location
Wednesday October 10th 7:30 am - Registration Opens 8:30 am - Welcome, Announcements and Keynote Speaker Introduction Karl Salzwedel, NIAID 8:40 am - Keynote I: Anthony Fauci, NIAID Martin Delaney Collaboratory Research Highlights 9:00 am - I4C: Combined Immunological Approaches to Cure HIV-1 Dan Barouch, Beth Israel Deaconess Medical Center 9:20 am - BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy Luis Montaner, Wistar Institute 9:40 am - BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication Douglas Nixon, Weill Cornell Medicine 10:00 am - CARE: Collaboratory of AIDS Researchers for Eradication David Margolis, University of North Carolina, Chapel Hill 10:20 am - defeatHIV: Delaney Cell and Genome Engineering Initiative Keith Jerome, Fred Hutchinson Cancer Research Center 10:40 am - DARE: Delaney AIDS Research Enterprise to Cure HIV Steven Deeks, University of California, San Francisco 11:00 am - Break (Poster Viewing and Networking) Session I: Finding the Reservoir * Chairs: Janice Clements, Johns Hopkins University and Elizabeth Connick, University of Arizona 11:25 am - HIV-1 Modulates Host Gene Expression at the Integration Site Ya-Chi Ho, Yale School of Medicine 11:40 am - Characterizing Host Pathways that Regulate Latency in a Primary Cell Model Edward Browne, University of North Carolina, Chapel Hill 11:55 am - Characterization of Latent and Active HIV Reservoirs in Blood and Tissues Nicolas Chomont, Université de Montréal 12:10 pm - Novel In Situ Approaches to Characterize Viral Reservoirs Jacob Estes, Oregon Health & Science University 12:25 pm - Developing Imaging Approaches to Define the Early Mucosal SIV Reservoir Thomas Hope, Northwestern University 12:40 pm - Panel Discussion 1:00 pm - Lunch (On Your Own) 2:00 pm - Poster Session Session II: Quantifying the Reservoir * Chairs: Nancie Archin, University of North Carolina, Chapel Hill and John Mellors, University of Pittsburgh 3:15 pm - Genomic Landscapes of HIV, SIV, and SHIV: Relevance to Measuring the Latent Reservoir in Cure Studies Robert Siliciano, Johns Hopkins University 3:30 pm - Insights into HIV Reservoir Assay Performance from the RAVEN Program Michael Busch, Blood Systems Research Institute 3:45 pm - Determining Early HIV Decay Dynamics upon Treatment Initiation Elizabeth Anderson, HIV Dynamics and Replication Program, NCI 4:00 pm - A Phylogenetic Approach to Estimate Integration Dates of Individual Latent HIV Sequences Within-Host Zabrina Brumme, Simon Fraser University 4:15 pm - Using Reactivation Rates to Quantify the Viral Reservoir Brandon Keele, AIDS and Cancer Virus Program, NCI 4:30 pm - Panel Discussion 5:00 pm - Adjourn Day 1
7:30 am - Registration Opens 8:30 am - Welcome, Announcements and Keynote Speaker Introduction Karl Salzwedel, NIAID 8:40 am - Keynote I: Anthony Fauci, NIAID
9:00 am - I4C: Combined Immunological Approaches to Cure HIV-1 Dan Barouch, Beth Israel Deaconess Medical Center 9:20 am - BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy Luis Montaner, Wistar Institute 9:40 am - BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication Douglas Nixon, Weill Cornell Medicine 10:00 am - CARE: Collaboratory of AIDS Researchers for Eradication David Margolis, University of North Carolina, Chapel Hill 10:20 am - defeatHIV: Delaney Cell and Genome Engineering Initiative Keith Jerome, Fred Hutchinson Cancer Research Center 10:40 am - DARE: Delaney AIDS Research Enterprise to Cure HIV Steven Deeks, University of California, San Francisco 11:00 am - Break (Poster Viewing and Networking)
Chairs: Janice Clements, Johns Hopkins University and Elizabeth Connick, University of Arizona
11:25 am - HIV-1 Modulates Host Gene Expression at the Integration Site Ya-Chi Ho, Yale School of Medicine 11:40 am - Characterizing Host Pathways that Regulate Latency in a Primary Cell Model Edward Browne, University of North Carolina, Chapel Hill 11:55 am - Characterization of Latent and Active HIV Reservoirs in Blood and Tissues Nicolas Chomont, Université de Montréal 12:10 pm - Novel In Situ Approaches to Characterize Viral Reservoirs Jacob Estes, Oregon Health & Science University 12:25 pm - Developing Imaging Approaches to Define the Early Mucosal SIV Reservoir Thomas Hope, Northwestern University 12:40 pm - Panel Discussion 1:00 pm - Lunch (On Your Own) 2:00 pm - Poster Session
Chairs: Nancie Archin, University of North Carolina, Chapel Hill and John Mellors, University of Pittsburgh 3:15 pm - Genomic Landscapes of HIV, SIV, and SHIV: Relevance to Measuring the Latent Reservoir in Cure Studies Robert Siliciano, Johns Hopkins University 3:30 pm - Insights into HIV Reservoir Assay Performance from the RAVEN Program Michael Busch, Blood Systems Research Institute 3:45 pm - Determining Early HIV Decay Dynamics upon Treatment Initiation Elizabeth Anderson, HIV Dynamics and Replication Program, NCI 4:00 pm - A Phylogenetic Approach to Estimate Integration Dates of Individual Latent HIV Sequences Within-Host Zabrina Brumme, Simon Fraser University 4:15 pm - Using Reactivation Rates to Quantify the Viral Reservoir Brandon Keele, AIDS and Cancer Virus Program, NCI 4:30 pm - Panel Discussion 5:00 pm - Adjourn Day 1
Thursday October 11th 8:25 AM - Announcements and Keynote Speaker Introduction Lillian Kuo, NIAID 8:30 AM - Keynote II: CD4-mimetic Compounds: Sensitization of HIV-1 to Sub-dominant Antibody Responses Joseph Sodroski, Dana-Farber Cancer Institute Session III: Overcoming Latency * Chairs: Richard D’Aquila, Northwestern University and Vicente Planelles, University of Utah 9:00 am - Dual TLR2 and TLR7 Agonists as HIV Latency-reversing Agents Amanda Macedo, George Washington University 9:15 am - BCL-2 Antagonism Enables CTL-Mediated Elimination of Ex Vivo CD4 Reservoirs R. Brad Jones, Weill Cornell Medicine 9:30 am - Systemic In Vivo Induction of the Latent HIV Reservoir via the Non-canonical NF-kB Signaling Pathway J. Victor Garcia, University of North Carolina, Chapel Hill 9:45 am - Latency Reversal in Nonhuman Primates Ann Chahroudi, Emory University 10:00 am - Combination Therapies with TLR7 Agonists Devi SenGupta, Gilead Sciences 10:15 am - Panel Discussion 10:45 am - Break (Poster Viewing and Networking) Session IV: Killing Reservoir Cells * Chairs: Sharon Riddler, University of Pittsburgh and Lydie Trautmann, Military HIV Research Program 11:05 am - Towards HIV-1 Remission with AAV-expressed eCD4-Ig Matthew Gardner, Scripps Research Institute 11:20 am - How Many mAbs to Target the Latent Reservoir? Guido Ferrari, Duke University 11:35 am - Novel Humanized Mouse Model to Investigate In Vivo Activation and bNAb-mediated Depletion of Patient-Derived HIV Latent Reservoirs Harris Goldstein, Albert Einstein College of Medicine 11:50 am - Trafficking of Stem Cell-Derived CAR T-Cells to B-Cell Follicles in SHIV-Infected Nonhuman Primates Christopher Peterson, Fred Hutchinson Cancer Research Center 12:05 pm - Why HIV-specific T cells Engineered with CARs Work Better than Those Engineered with TCRs James Riley, University of Pennsylvania 12:20 pm - HIV-Resistant CAR T Cells in SHIV-infected Non-human Primates Thor Wagner, Seattle Children's Hospital 12:35 pm - Panel Discussion 1:00 pm - Lunch (On Your Own) 2:00 pm - Poster Session Session V: Immunomodulation and Immunologic Control of Viremia * Chairs: Jonathan Karn, Case Western Reserve University and Jeffrey Lifson, Frederick National Laboratory 3:00 pm - Understanding CD8+ T Cell Function During Antiretroviral Therapy Afam Okoye, Oregon Health & Science University 3:15 pm - Generating Functional HIV-specific CD8+ T Cells Rachel Rutishauser, University of California, San Francisco 3:30 pm - Myeloid-derived Suppressor Cells Expand During Analytic treatment Interruption and Decrease Anti-viral T cell Responses in Combinatorial HIV Curative Therapy Sandra Dross, University of Washington 3:45 pm - Combination Immunotherapy to Induce Viral Remission James Whitney, Beth Israel Deaconess Medical Center 4:00 pm - Neutralizing Antibody-Based HIV Cure Strategies Dan Barouch, Beth Israel Deaconess Medical Center 4:15 pm - Effects of Broadly Neutralizing Antibody Combinations in HIV-1 Infection Marina Caskey, Rockefeller University 4:30 pm - Panel Discussion 5:00 pm - Adjourn Day 2
8:25 AM - Announcements and Keynote Speaker Introduction Lillian Kuo, NIAID 8:30 AM - Keynote II: CD4-mimetic Compounds: Sensitization of HIV-1 to Sub-dominant Antibody Responses Joseph Sodroski, Dana-Farber Cancer Institute
Chairs: Richard D’Aquila, Northwestern University and Vicente Planelles, University of Utah 9:00 am - Dual TLR2 and TLR7 Agonists as HIV Latency-reversing Agents Amanda Macedo, George Washington University 9:15 am - BCL-2 Antagonism Enables CTL-Mediated Elimination of Ex Vivo CD4 Reservoirs R. Brad Jones, Weill Cornell Medicine 9:30 am - Systemic In Vivo Induction of the Latent HIV Reservoir via the Non-canonical NF-kB Signaling Pathway J. Victor Garcia, University of North Carolina, Chapel Hill 9:45 am - Latency Reversal in Nonhuman Primates Ann Chahroudi, Emory University 10:00 am - Combination Therapies with TLR7 Agonists Devi SenGupta, Gilead Sciences 10:15 am - Panel Discussion 10:45 am - Break (Poster Viewing and Networking)
Chairs: Sharon Riddler, University of Pittsburgh and Lydie Trautmann, Military HIV Research Program 11:05 am - Towards HIV-1 Remission with AAV-expressed eCD4-Ig Matthew Gardner, Scripps Research Institute 11:20 am - How Many mAbs to Target the Latent Reservoir? Guido Ferrari, Duke University 11:35 am - Novel Humanized Mouse Model to Investigate In Vivo Activation and bNAb-mediated Depletion of Patient-Derived HIV Latent Reservoirs Harris Goldstein, Albert Einstein College of Medicine 11:50 am - Trafficking of Stem Cell-Derived CAR T-Cells to B-Cell Follicles in SHIV-Infected Nonhuman Primates Christopher Peterson, Fred Hutchinson Cancer Research Center 12:05 pm - Why HIV-specific T cells Engineered with CARs Work Better than Those Engineered with TCRs James Riley, University of Pennsylvania 12:20 pm - HIV-Resistant CAR T Cells in SHIV-infected Non-human Primates Thor Wagner, Seattle Children's Hospital 12:35 pm - Panel Discussion 1:00 pm - Lunch (On Your Own) 2:00 pm - Poster Session
Chairs: Jonathan Karn, Case Western Reserve University and Jeffrey Lifson, Frederick National Laboratory 3:00 pm - Understanding CD8+ T Cell Function During Antiretroviral Therapy Afam Okoye, Oregon Health & Science University 3:15 pm - Generating Functional HIV-specific CD8+ T Cells Rachel Rutishauser, University of California, San Francisco 3:30 pm - Myeloid-derived Suppressor Cells Expand During Analytic treatment Interruption and Decrease Anti-viral T cell Responses in Combinatorial HIV Curative Therapy Sandra Dross, University of Washington 3:45 pm - Combination Immunotherapy to Induce Viral Remission James Whitney, Beth Israel Deaconess Medical Center 4:00 pm - Neutralizing Antibody-Based HIV Cure Strategies Dan Barouch, Beth Israel Deaconess Medical Center 4:15 pm - Effects of Broadly Neutralizing Antibody Combinations in HIV-1 Infection Marina Caskey, Rockefeller University 4:30 pm - Panel Discussion 5:00 pm - Adjourn Day 2
Friday October 12th 8:25 AM - Announcements and Keynote Speaker Introduction Roger Miller, NIAID 8:30 AM - Keynote III: Silencing the HIV-1 Reservoir Susana Valente, Scripps Research Institute Session VI: Clinical Trials and Community Engagement * Chairs: Adriana Andrade, NIAID and Joseph Eron, University of North Carolina, Chapel Hill Panelists: Richard Jeffreys, Treatment Action Group and A. Toni Young, Community Education Group 9:00 am - Meeting Report: Framework for Initiating Pediatric Studies of HIV Cure Interventions Deborah Persaud, Johns Hopkins University 9:15 am - Analytical Treatment Interruption in HIV Cure Trials – Report of a Consensus Workshop Boris Juelg, Ragon Institute 9:30 am - Acceptability of Target Product Profiles for an HIV Cure Regimen According to Adults Living with HIV in the U.S. Karine Dubé, University of North Carolina, Chapel Hill 9:45 am - The Last Gift: Performing HIV Cure Research at the End of Life Sara Gianella Weibel, University of California, San Diego 10:00 am - Panel Discussion 10:30 am - Break (Poster Viewing and Networking) Session VII: Viral Rebound and Post Treatment Control * Chairs: Rajesh Gandhi, Massachusetts General Hospital and Nelson Michael, Military HIV Research Program 10:50 am - Lessons Learned from Brief ATI Trials in the RV254 Cohort to Inform Future ATI Designs Jintanat Ananworanich, Military HIV Research Program 11:05 am - Preliminary Testing of a bNAb Susceptibility Screening Assay Katherine Bar, University of Pennsylvania 11:20 am - The Majority of the Replication-competent Virus in the Latent Reservoir Originates from Viruses Replicating Near the Time of ART Initiation Sarah Joseph, University of North Carolina, Chapel Hill 11:35 am - Impact of Analytical Treatment Interruption on HIV Dynamics Tae-Wook Chun, NIAID 11:50 am - Understanding Post-Treatment HIV Control Jonathan Li, Brigham and Women's Hospital 12:05 pm - Panel Discussion 12:30 pm - Closing Remarks, Adjourn
8:25 AM - Announcements and Keynote Speaker Introduction Roger Miller, NIAID 8:30 AM - Keynote III: Silencing the HIV-1 Reservoir Susana Valente, Scripps Research Institute
Chairs: Adriana Andrade, NIAID and Joseph Eron, University of North Carolina, Chapel Hill Panelists: Richard Jeffreys, Treatment Action Group and A. Toni Young, Community Education Group 9:00 am - Meeting Report: Framework for Initiating Pediatric Studies of HIV Cure Interventions Deborah Persaud, Johns Hopkins University 9:15 am - Analytical Treatment Interruption in HIV Cure Trials – Report of a Consensus Workshop Boris Juelg, Ragon Institute 9:30 am - Acceptability of Target Product Profiles for an HIV Cure Regimen According to Adults Living with HIV in the U.S. Karine Dubé, University of North Carolina, Chapel Hill 9:45 am - The Last Gift: Performing HIV Cure Research at the End of Life Sara Gianella Weibel, University of California, San Diego 10:00 am - Panel Discussion 10:30 am - Break (Poster Viewing and Networking)
Chairs: Rajesh Gandhi, Massachusetts General Hospital and Nelson Michael, Military HIV Research Program 10:50 am - Lessons Learned from Brief ATI Trials in the RV254 Cohort to Inform Future ATI Designs Jintanat Ananworanich, Military HIV Research Program 11:05 am - Preliminary Testing of a bNAb Susceptibility Screening Assay Katherine Bar, University of Pennsylvania 11:20 am - The Majority of the Replication-competent Virus in the Latent Reservoir Originates from Viruses Replicating Near the Time of ART Initiation Sarah Joseph, University of North Carolina, Chapel Hill 11:35 am - Impact of Analytical Treatment Interruption on HIV Dynamics Tae-Wook Chun, NIAID 11:50 am - Understanding Post-Treatment HIV Control Jonathan Li, Brigham and Women's Hospital 12:05 pm - Panel Discussion 12:30 pm - Closing Remarks, Adjourn
*Sessions will be comprised of short 12-minute talks in a total 15-minute slot per speaker, then followed by a 20 to 30-minute panel discussion with all speakers